

CAD for MRI of the Breast (E&I)

Policy Number: MP-140
Last Review Date: 05/09/2019
Effective Date: 07/01/2019

MP.140 – CAD for MRI of the Breast - Experimental

Evolent Health considers **Computer Aided Detection (CAD) for MRI of the Breast** to be *experimental and investigational and therefore not covered*.

Background

According to the Centers for Disease Control and Prevention (CDC), breast cancer is the second most common cancer among women in the U.S.

Computer-aided detection (CAD) software can identify characteristics of malignancy on digital images and thus can decrease interobserver variability. The goal of CAD is to improve detection while minimizing false-negatives.

Current clinical evidence does not yet demonstrate that CAD for MRI of the breast improves patient outcomes or reduces breast cancer mortality. Additional studies are needed to determine if CAD for MRI of the breast can maintain or increase the sensitivity, specificity and recall rates.

Codes

The following is NOT a covered code:

CPT	Description
0159T	Computer-aided detection, including computer algorithm analysis of MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI

Related Policies

MP.057 – Mammography, Computer-Aided Detection (CAD)

References

1. Centers for Disease Control and Prevention (CDC). Breast Cancer. Last updated November 09, 2018. <https://www.cdc.gov/cancer/breast/>
2. Computer-aided detection of malignancy with magnetic resonance imaging of the breast. Technol Eval Cent Assess Program Exec Summ. 2006 Jun;21(4):1-3. <https://www.ncbi.nlm.nih.gov/pubmed/16832927>
3. Hayes. Search & Summary. Computer-Aided Detection (CAD) for Magnetic Resonance Imaging of Breast Lesions. March 26, 2015.

MP.140: CAD for MRI of Breast (E&I)

Policy Number: MP.140.MH

Last Review Date: 05/09/2019

Effective Date: 07/01/2019

4. Hayes. Medical Technology Directory. Computer-Aided Detection (CAD) with Full-Field Digital Mammography (FFDM) for Breast Cancer Screening. Annual Review December 10, 2018.

Disclaimer:

Evolent Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Evolent Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Evolent Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.